2 results match your criteria: "Shizuoka Institute of Epilepsy and Neurological Disorders 886[Affiliation]"
Neurosci Lett
January 2021
Department of Psychiatry, Yokohama City University Graduate School of Medicine 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
Introduction: Mild cognitive dysfunction has been implicated in a number of psychiatric diseases and affects social functioning. Although clinical criteria were recently proposed for autoimmune psychosis (AP), biomarkers have not yet been established for the severity and prognosis of cognitive dysfunction. We herein investigated the relationships between 3 types of serum antibodies and cognitive dysfunction in chronic psychiatric patients suspected of AP.
View Article and Find Full Text PDFEpilepsy Res
November 2016
Department of Clinical Research, National Epilepsy Center, NHO, Shizuoka Institute of Epilepsy and Neurological Disorders 886, Urushiyama, Shizuoka, 420-8688, Japan.
The aim of this study was to evaluate the influence of antiepileptic drugs (AEDs) on lipid levels in adult epilepsy patients. We retrospectively reviewed blood data of 5053 patients with epilepsy (aged 20-94 years) and divided them into 3 groups: non AED group (without AED treatment), non-inducer group (using non-inducer AEDs), and inducer group (taking inducer AEDs; phenytoin (PHT), phenobarbital (PB), and carbamazepine (CBZ)). As a marker of dyslipidemia, the level of non-high-density lipoprotein cholesterol (non-HDL-C) was calculated by subtracting HDL-cholesterol from total cholesterol.
View Article and Find Full Text PDF